...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >SCREENING OF COMMON SIDDHA FORMULATIONS FOR ANTIMICROBIAL ACTIVITY AGAINST RESPIRATORY PATHOGENS
【24h】

SCREENING OF COMMON SIDDHA FORMULATIONS FOR ANTIMICROBIAL ACTIVITY AGAINST RESPIRATORY PATHOGENS

机译:常见的SIDHA配方对呼吸道病原菌抗微生物活性的筛选

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: The objective of this study was to screen the antimicrobial potential and minimal inhibitory concentrations (MICs) of selected commonlyused Siddha formulations against respiratory pathogens.Methods: The most frequently and clinically used Siddha formulations for respiratory infections, namely Gowri chinthamani (R1), Sivanar amirtham(R2), Poorana chandrodayam (R3), Thalaga parpam (R4), Pavala parpam (R5), and Vasantha kusumasura mathirai (R6) were screened for antimicrobialactivity against microbial type culture collection strains of Neisseria mucosa, Klebsiella pneumonia, Streptococcus pneumonia, Staphylococcus aureus,Pseudomonas aeruginosa, and Aspergillus niger, respectively, by agar well diffusion method. Tetracycline and fluconozole were used as positive controlfor bacterial and fungal pathogens, respectively. The zone of inhibition and the MICs were determined.Results: Among these formulations, Sivanar amirtham (R2) and Pavala parpam (R5) showed microbial sensitivity against all the above testedrespiratory pathogens. The drug Sivanar amirtham (R2) showed higher zone of inhibition when compared to the control tetracycline.Conclusion: The study, therefore, supports the clinical claims of Siddha formulations to have potent antimicrobial activity and offer profoundtherapeutic benefits in respiratory infections.
机译:目的:本研究的目的是筛选选定的常用西达制剂对呼吸道病原体的抗菌潜力和最低抑菌浓度(MIC)。筛选了Sivanar amirtham(R2),Chordaydayam(Porana chandrodayam)(R3),Thalaga parpam(R4),Pavala parpam(R5)和Vasantha kusumasura mathirai(R6)对细菌性黏膜奈瑟氏菌,肺炎克雷伯氏菌,肺炎克雷伯氏菌琼脂井扩散法分别测定金黄色葡萄球菌,铜绿假单胞菌和黑曲霉。四环素和氟康唑分别用作细菌和真菌病原体的阳性对照。结果:在这些制剂中,Sivanar amirtham(R2)和Pavala parpam(R5)对上述所有测试的呼吸道病原体均表现出微生物敏感性。与对照四环素相比,Sivanar amirtham(R2)药物具有更高的抑制范围。结论:因此,该研究支持Siddha制剂的临床声称具有有效的抗菌活性,并在呼吸道感染中具有深远的治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号